BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Most Moving TED Talks You Want to Watch - 2Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- 3Moscow: Russia well-positioned to withstand oil market shocks
- 4Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
- 5Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- Burkina Faso forces killed twice as many civilians as jihadists, rights group says
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- NASA's Voyager 1 set to achieve historic distance from Earth
- Smuggler who called migrants 'chickens' jailed
- The 10 Most Significant Virtual Entertainment Missions
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- Conquering Social Generalizations: Individual Accounts of Strengthening
- NAFFIC, AWARE claim first China-EU DPP for textiles
